All In Biotech

NDA 209112 · Mcguff

Ascor

Ascorbic Acid · Intravenous · Vitamin C

Orphan

Last checked: Nov 19, 2026Latest source record: Jan 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Oct 2, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

617

128 Phase 3, 49 recruiting

FAERS reports

23,363

16,695 serious, 2,648 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 29, 2026.

1. INDICATIONS AND USAGE ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy. ASCOR is vitamin C indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. Limitations of Use ASCOR is not indicated for treatment of vitamin C deficiency that is not associated with signs and symptoms of scurvy.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 2017 Original approval · Type 7 - Drug Already Marketed without Approved NDA OrphanLabelLetterReview
1 products under this application
  • ASCOR · ASCORBIC ACID 25,000MG/50ML (500MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ascorbic Acid" as an intervention, any sponsor and status, largest first.

All 617 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,366
  • pain2,120
  • nausea2,025
  • diarrhoea1,860
  • headache1,830
  • drug ineffective1,800
  • dyspnoea1,711
  • off label use1,601
  • vomiting1,585
  • asthenia1,491
  • rash1,425
  • dizziness1,363

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004369
2005810
2006875
2007890
20081,126
20091,295
20101,093
20111,802
20121,842
2013428
2014485
2015493
2016661
2017794
20181,056
20191,037
20201,325
20211,279
20221,328
20231,222
20241,306
20251,093
2026753

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,305 on PubMed

Sponsor: Mcguff

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.